Quality of life among patients with epilepsy in Nigeria: predictors and barriers to routine clinical use of QOLIE-31.

PURPOSE: To determine the factors predicting poorer quality of life (QOL) among patients with epilepsy attending an out-patient clinic in a Nigerian tertiary hospital, and reflect on the barriers to successful adoption of a structured QOL instrument into routine clinical practice. METHODS: Two-hundred and seventy patients with a diagnosis of epilepsy attending the Neuropsychiatric Hospital, Abeokuta, Nigeria were recruited. Sociodemographic and clinical information were collected using a proforma. QOLIE-31 was administered to measure QOL. RESULTS: The mean (SD) QOLIE-31 scores were 77.98 (13.32), with 15.2%, 74.1%, and 10.7% of the respondents classified as low, moderate, and high QOL, respectively. Factors associated with poorer QOL include seizure frequency, depression, and family history of epilepsy. CONCLUSION: Quality of life is an important outcome measure for people with epilepsy and it focuses on the individual's subjective assessment of their well-being. Although useful for clinical management of patients with epilepsy, the uniqueness of the practice settings and the limitations of clinical practice in a developing country pose challenges to successful adoption of structured QOL instrument into routine clinical practice.

Correlates of depression and quality of life among patients with epilepsy in Nigeria.

OBJECTIVES: To determine the prevalence of Major Depressive Disorders (MDD) and its relationship to Quality of life. DESIGN: A cross-sectional observational study. SETTING: Out-Patient Clinic of the Neuropsychiatric Hospital, Abeokuta, Nigeria. SUBJECTS: Patients with diagnosis of Epilepsy with Electroencephalogram (EEG) confirmation. OUTCOME MEASURES: Depression and Quality of life. RESULTS: The prevalence of current MDD was 11.9 %, and patients having at least 1 seizure per week were 5 times more likely to develop MDD (OR = 5.104, p = 0.014). The mean (SD) QOLIE-31 scores was 77.98 (13.32), with presence of MDD (ß = -11.101, p = 0.0001); having at least 1 seizure/week (ß = -6.653, p = 0.037) being independent predictors. CONCLUSION: Depression is a common comorbidity in patients with epilepsy and is associated with a lower quality of life.

Comparative assessment of quality of life of patients with schizophrenia attending a community psychiatric centre and a psychiatric hospital.

BACKGROUND: Over the past few decades, there has been an emphasis on the de-institutionalisation of psychiatric care with a focus on community care. With Quality of Life (QoL) as an outcome measure, this study compared the QoL of patients with schizophrenia attending a psychiatric hospital and a community psychiatric centre. DESIGN: This was a cross-sectional study in two psychiatric facilities. METHODS: Data were obtained through a socio-demographic and clinical questionnaire; the QoL was assessed with the WHOQOL-BREF and patient satisfaction with care with CPOSS. Total and domain scores of WHOQOL-BREF for each group were calculated and compared with each other and other group characteristics. Diagnosis of schizophrenia was based on ICD-10. RESULTS: Participants from the two centres did not differ significantly on any of the socio-demographic characteristics measured. Similarly, there was no significant difference in their overall mean WHOQOL-BREF scores as well as the mean WHOQOL-BREF of domain scores. However, the married and females from both centres significantly had higher mean WHOQOL-BREF scores than their male counterparts. Patients in remission for more than two years or those on a single type of medication (either oral or depot preparation) from both centres significantly had higher mean WHOQOL-BREF score compared with those who had less than two years of remission or on both oral and depot preparations. CONCLUSION: Overall QoL of patients managed at the two centres was comparable, with similar socio-demographic as well as clinical variables influencing QoL. This suggests that patients with schizophrenia can be well managed at community psychiatric centres. FUNDING: None declared.